Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GALR3 | O60755 | 1/20 | 0.40 |
| ▸ | SLC6A9 | P48067 | 4/20 | 0.37 |
| ▸ | CARM1 | Q86X55 | 2/20 | 0.34 |
| ▸ | PRMT6 | Q96LA8 | 2/20 | 0.34 |
| ▸ | PARP1 | P09874 | 1/20 | 0.33 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.33 |
| ▸ | TACR1 | P25103 | 1/20 | 0.32 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.32 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.32 |
| ▸ | F2 | P00734 | 1/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.32 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.31 |
| ▸ | MLNR | O43193 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL615031 | 0.92 | SLC6A9 (0.40) | GALR3SLC6A9CARM1PRMT6PARP1 | |
| SCHEMBL606718 | 0.90 | SLC6A9 (0.43) | GALR3SLC6A9CARM1PRMT6PARP1 | |
| SCHEMBL615092 | 0.90 | SLC6A9 (0.39) | SLC6A9CARM1PRMT6KCNH2TRPV1 | |
| SCHEMBL617344 | 0.89 | SLC6A9 (0.46) | SLC6A9KCNH2 | |
| SCHEMBL617452 | 0.89 | SLC6A9 (0.38) | SLC6A9CARM1PRMT6KCNH2 | |
| SCHEMBL615918 | 0.88 | GALR3 (0.44) | GALR3SLC6A9CARM1PRMT6PARP1 | |
| SCHEMBL615463 | 0.87 | GALR3 (0.35) | GALR3SLC6A9CARM1PRMT6PARP1 | |
| SCHEMBL615535 | 0.87 | GALR3 (0.41) | GALR3SLC6A9KCNH2 | |
| SCHEMBL614482 | 0.85 | SLC6A9 (0.46) | GALR3SLC6A9CARM1PRMT6TRPV4 | |
| SCHEMBL614428 | 0.84 | SLC6A9 (0.43) | GALR3SLC6A9CARM1PRMT6PARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9051280-B2 | Tetraline and indane derivatives, pharmaceutical compositions containing them, and their use in therapy | AbbVie Deutschland GmbH & Co. KG (DE) | 2015-06-09 | — | — | US | claimed |
| US-8883839-B2 | Tetraline and indane derivatives, pharmaceutical compositions containing them, and their use in therapy | ABBOTT LABORATORIES (US) | 2014-11-11 | — | — | US | claimed |
| US-20120295881-A1 | TETRALINE AND INDANE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | ABBOTT GMBH & CO. KG (DE) | 2012-11-22 | — | — | US | claimed |
| US-20120040947-A1 | TETRALINE AND INDANE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | ABBOTT LABORATORIES (US) | 2012-02-16 | — | — | US | claimed |
| US-9051280-B2 | Tetraline and indane derivatives, pharmaceutical compositions containing them, and their use in therapy | AbbVie Deutschland GmbH & Co. KG (DE) | 2015-06-09 | — | — | US | disclosed |
| US-8883839-B2 | Tetraline and indane derivatives, pharmaceutical compositions containing them, and their use in therapy | ABBOTT LABORATORIES (US) | 2014-11-11 | — | — | US | disclosed |
| US-8883839-B2 | Tetraline and indane derivatives, pharmaceutical compositions containing them, and their use in therapy | ABBOTT LABORATORIES (US) | 2014-11-11 | — | — | US | disclosed |
| US-20120295881-A1 | TETRALINE AND INDANE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | ABBOTT GMBH & CO. KG (DE) | 2012-11-22 | — | — | US | disclosed |
| WO-2012020133-A1 | TETRALINE AND INDANE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | ABBOTT GMBH & CO. KG (DE) | 2012-02-16 | — | — | WO | disclosed |
| US-20120040947-A1 | TETRALINE AND INDANE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | ABBOTT LABORATORIES (US) | 2012-02-16 | — | — | US | disclosed |
| US-20120040947-A1 | TETRALINE AND INDANE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | ABBOTT LABORATORIES (US) | 2012-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120040947-A1 | TETRALINE AND INDANE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | SLC10A1, SUGT1, SLC10A2 | GALR3 462/4885SLC6A9 42/4885CARM1 1742/4885 |
| US-20120295881-A1 | TETRALINE AND INDANE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | SLC10A1, SUGT1, SLC10A2 | GALR3 462/4885SLC6A9 42/4885CARM1 1742/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.